Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Egetis Therapeutics AB ( (SE:EGTX) ) is now available.
Egetis Therapeutics’ 2025 annual report outlines its progress and strategic focus in rare disease therapies, highlighting Emcitate for MCT8 deficiency and Aladote as key assets. The report emphasizes commercialization plans in Europe and launch preparations for the U.S. market, details around potential new indications such as RTH‑beta, and discusses sustainability, risk management, and corporate governance, underscoring the company’s efforts to build a competent organization and strengthen its position in the orphan drug market.
The most recent analyst rating on (SE:EGTX) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Egetis Therapeutics AB stock, see the SE:EGTX Stock Forecast page.
More about Egetis Therapeutics AB
Egetis Therapeutics AB is a Stockholm‑based pharmaceutical company listed on Nasdaq Stockholm under the ticker EGTX. The company focuses on developing and commercializing treatments for rare diseases, notably its lead products Emcitate and Aladote, targeting orphan drug segments with associated market exclusivity.
Average Trading Volume: 785,374
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.96B
Find detailed analytics on EGTX stock on TipRanks’ Stock Analysis page.